Agios Pharmaceuticals 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Agios reported record 3rd quarter 2026 total net revenue of $55.4 million, more than 4 times the 3rd quarter of 2025, including $48.7 million in the U.S. and $6.6 million outside the U.S.
- Total net revenue in the 3rd quarter of 2025 was $12.9 million; the company said 3rd quarter 2026 revenue exceeded its total revenue for all of 2025.
- Cost of sales was $2.5 million, compared with $1.7 million in the prior-year period; research and development expense was $73.5 million, compared with $86.8 million; and selling, general and administrative expense was $56.5 million, compared with $41.3 million.
- Net loss for the 3rd quarter of 2026 was $65 million, compared with $103.4 million in the 3rd quarter of 2025.
- Agios ended the quarter with $907 million in cash, cash equivalents, and marketable securities.
- In thalassemia, the company reported 619 prescriptions with completed Agios Start forms since launch, roughly 15% of its target launch population of about 4,000 patients, plus 48 prescriptions with forms in process at quarter end.
- Approximately 75% of patients remained on therapy at about 6 months, with management reporting strong persistency across transfusion-dependent and non-transfusion-dependent patient segments.
- U.S. net revenue increased 20% sequentially, while net revenue outside the U.S. increased 74% versus the prior quarter, driven by early access programs in Europe following European Commission approval in the 2nd quarter.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning and welcome to Agios Pharmaceuticals third quarter 2026 conference call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session at the end. Please be advised that this call is being recorded at Agios' request. I would now like to turn the call over to Morgan Sanford, Vice President of Investor Relations at Agios. Thank you. Please go ahead.
Thank you, operator. Good morning, everyone. Thank you for joining us to discuss Agios Pharmaceuticals third quarter 2026 financial results and business highlights. You can access the slides for today's call by going to the Investors section of our website, agios.com. Next slide, please. Please note, we will be making certain forward-looking statements today. Actual events and results could differ materially from those expressed or implied by any forward-looking statements because of various risks, uncertainties, and other factors, including those set forth in our most recent filings with the SEC and any other future filings that we may make with the SEC. On the next slide, we have the agenda for today's call. With me today from Agios are Brian Goff, Chief Executive Officer, Cecilia Jones, Chief Financial Officer, Tsveta Milanova, Chief Commercial Officer, and Dr. Sarah Gheuens, Chief Medical Officer and Head of Research and Development.
Following prepared remarks, we will open the call for questions. With that, I am pleased to turn the call over to Brian.
Thanks, Morgan. Good morning, everyone, and thank you for joining us. Next slide, please. The third quarter delivered record product revenue for Agios and is a clear demonstration of our commercial execution. We delivered $55.4 million in total net revenue, more than four times the third quarter of last year. U.S. net revenue was $48.7 million, driven by the continued strong U.S. launch of AQVESME in thalassemia. To put that in perspective, in a single quarter, we generated more total revenue than we did in all of 2025. This performance reflects what we are building, a focused rare hematology company with a scalable commercial foundation. Thalassemia is the first launch to leverage that foundation. Sickle cell disease, our largest opportunity, is next, and I will speak to the status of our mitapivat NDA in a moment.
We ended the quarter with $907 million in cash equivalents, and marketable securities, and are well capitalized to support commercial launches and development of our focused pipeline. Next slide, please. As I mentioned, we have the pieces in place to deliver on the commercial launch of mitapivat in sickle cell disease. Let me take a moment to directly address our recent update on our NDA. As we disclosed last week on October 9, the FDA asked for additional information to evaluate whether a Risk Evaluation and Mitigation Strategy, or REMS, is necessary for mitapivat in sickle cell disease. We responded within 10 days, including approximately nine months of additional safety data from the RISE UP open-label extension period. The FDA classified our response as a major amendment, which procedurally extends the review timeline by three months to February 1, 2027.
Let me be clear on why we remain confident in a potential approval in sickle cell disease. With this additional follow-up, there continues to be no cases of liver injury in sickle cell disease similar in pattern or severity to those seen in thalassemia. The benefit-risk profile for mitapivat in sickle cell disease is unchanged. The FDA granted this application priority review, recognizing the serious unmet need, and that urgency has not changed. We are in ongoing labeling negotiations with the agency, including elements of a potential REMS, and we are launch-ready. Our commercial, medical, market access, and patient support teams are in place, and we continue to engage closely with the sickle cell community. Our focus is on bringing mitapivat to patients as quickly as possible. Next slide, please. Looking ahead, we are sharpening our focus to drive the next phase of growth. Our strategy is clear. First, maximize the mitapivat franchise, which is now approved in PK deficiency and thalassemia, with sickle cell disease serving as another growth driver from early 2027.
Second, advance a focused rare hematology pipeline. That includes AG-236 in polycythemia vera, where we plan to initiate a phase II/III program by year-end, and cevidoplenib in immune thrombocytopenia, with a phase III trial planned for the first half of 2028. Importantly, both programs have clinically validated and de-risked mechanisms of action. To support that focus, we have right-sized our operating model. Over the course of 2026, we will have reduced R&D headcount by more than 35% compared with 2025, or more than 100 roles, and we expect associated cost savings to be realized in 2027. We are concentrating our clinical investment on differentiated rare hematology programs, and we are pursuing opportunities to unlock value from non-core assets, including our vorasidenib royalty and AG-181.
As a result, we will continue to manage operating expenses as we prioritize investment behind our commercial launches and rare hematology pipeline opportunities, and are targeting non-GAAP profitability in 2028. With that, please advance to the next slide, and I'll turn the call over to Cecilia to discuss financials.
Cecilia? Thank you, Brian. Next slide, please.
Turning to our third quarter financial results, total mitapivat net revenue was $55.4 million, including $48.7 million in the U.S. and $6.6 million outside the U.S., compared with $12.9 million in total net revenues in the third quarter of 2025. Cost of sales for the quarter was $2.5 million, compared to $1.7 million in the prior year period. Research and development expense was $73.5 million, compared to $86.8 million in the third quarter of 2025, primarily reflecting reductions in spend associated with mitapivat and tebapivat process development and certain clinical trials. Selling, general, and administrative expense was $56.5 million, compared to $41.3 million in the prior year period, reflecting commercial activities supporting the AQVESME U.S. launch in thalassemia and preparation for a potential U.S. sickle cell disease launch.
Net loss for the third quarter of 2026 was $65 million, compared to a net loss of $103.4 million in the third quarter of 2025. We ended the quarter with $907 million in cash equivalents, and marketable securities, which we believe provides the financial strength to support the AQVESME launch, a potential sickle cell disease launch, and progression of our focused pipeline into non-GAAP profitability in 2028. Turning to our 2026 outlook, full-year operating expenses are expected to remain approximately flat versus 2025, excluding the $25 million upfront payment associated with the cevidoplenib in-licensing, which was recognized in the second quarter, and an approximately $11 million one-time expense associated with the headcount reduction to be recognized in the fourth quarter. Please advance to the next slide, and I'll turn it over to Tsveta to cover commercial highlights.
Thank you, Cecilia. Next slide, please. The third quarter was a record quarter for mitapivat, and I'm proud of the execution across the teams, with total mitapivat revenues increasing more than four times the third quarter of last year. In the U.S., net revenue was up 20% sequentially, driven by AQVESME demand across the broad thalassemia population, which I will cover in more detail shortly. Outside the U.S., net revenue increased 74% versus the prior quarter, driven by early access programs in Europe following the European Commission approval for thalassemia in the second quarter. This is an early signal of the global opportunity for mitapivat, which we are pursuing through a capital-efficient model with our partners, Avanzanite in Europe and NewBridge Pharmaceuticals in the GCC. Next slide, please. Now, turning to U.S. demand for AQVESME in thalassemia.
As a reminder, an Agios Start Form is submitted with an AQVESME prescription when the patient and physician opt into our support program. In the third quarter, we added 177 prescriptions from REMS-certified physicians with completed start forms, bringing the total to 619 since launch, which is roughly 15% of our target launch population of about 4,000 patients, only three quarters into launch. This is the last quarter we'll report this metric, so for a complete picture, another 48 prescriptions had start forms in process at quarter end. We communicated previously that first quarter start forms benefited from pent-up demand built during the extended thalassemia FDA review periods. We are now seeing the steady broadening we planned for into community practices and non-transfusion-dependent patients, where treatment decisions take more time. On persistency, approximately 75% of patients remain on therapy at about six months.
This is exactly the foundation we want, a durable base of patients that build over time. Looking ahead, we are focused on two things. On persistency, making sure prescribers know the long-term clinical data we have generated so patients stay on treatment long enough to benefit. On demand, we are expanding our reach in the community setting, deepening adoption in transfusion-dependent patients, and driving uptake in non-transfusion-dependent patients. We are also activating patients themselves through the first direct-to-consumer campaign. Next slide, please. In August, we launched LEVEL UP with AQVESME, our first direct-to-consumer campaign, a targeted omnichannel effort. This month, we are expanding with multilingual assets to reach the diverse thalassemia community. Earlier results are encouraging, and after the launch, we saw a 65% increase in engagement on our patient website. Please move to the next slide. Feedback from treating physicians continues to reinforce the value of AQVESME in thalassemia.
Recent market research shows broad enthusiasm across both transfusion-dependent and non-transfusion-dependent segments. We are encouraged by the momentum three quarters into launch. As the first medicine approved for the broad thalassemia population, AQVESME is well-positioned for continued growth, and I'm confident in our team's ability to deliver. Next slide, please. Turning to sickle cell disease. As Brian said, we are launch-ready and will use the additional time to prepare even further ahead of our February 1st PDUFA goal date. There are approximately 75,000 diagnosed patients aged 16 and older in the U.S. Our initial launch focus is approximately 25,000 patients who are actively treated or in need of therapy, and we will prioritize these patients with hemolytic profile, defined by low or declining hemoglobin. This focused approach is designed to drive speed of adoption. This launch builds on the commercial foundation we established for thalassemia.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
16 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
